University of Massachusetts Boston

That dose level exceeds the MTD and no additional patients will be treated at that dose level or higher. Patients who are not evaluable for DLT should be replaced, including those taking enzyme-inducing anticonvulsant drugs whose PK values (increased clearance/decreased AUC) suggest interaction with CYP450 isoenzymes. ................
................